LAROSA JOSEPH J 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Nov 24, 2025
Insider Transaction Report
Form 4
LAROSA JOSEPH J
SVP Gen Counsel and Secretary
Transactions
- Tax Payment
Common Stock
2025-11-20$736.77/sh−12,686$9,346,664→ 22,839 total - Exercise/Conversion
Common Stock
2025-11-20$555.67/sh+14,450$8,029,431→ 35,525 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-20−14,450→ 0 totalExercise: $555.67Exp: 2025-12-16→ Common Stock (14,450 underlying)
Holdings
- 9,000(indirect: By 2024 GRAT)
Common Stock
- 9,000(indirect: By 2025 GRAT)
Common Stock
- 395(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The stock option award vested in four equal annual installments, commencing one year after the date of grant.